Compositions and methods for inhibiting rho kinase
AssigneesInterlude Biopharma Co., University of Maryland, College Park
InventorsYounggeon JIN, Nir BARAK, Jain KIM
Life of this patent
Estimating the term…
Abstract
The present invention provides for compositions and methods for treating a condition characterized by Rho-associated coiled-coil kinase (ROCK) activity in a subject in need thereof via administration of an effective amount of larazotide or larazotide derivative, or pharmaceutically acceptable salt thereof, to said subject in an amount and manner effective to inhibit ROCK activity in a tissue.
Claims32
A method for treating a subject for a condition characterized by Rho-associated coiled-coil kinase (ROCK) activity, comprising:
- administering an effective amount of larazotide or larazotide derivative, or pharmaceutically acceptable salt thereof, to said subject in an amount and manner effective to inhibit ROCK activity in a tissue.
The method of clam 1, wherein the tissue is the vasculature, and the subject optionally has a condition selected from cardiac fibrosis, cardiac hypertrophy, hypertension, pulmonary hypertension, angina pectoris, vasospastic angina, heart failure, and stroke.
The method of any one of the preceding claims, wherein the subject is administered larazotide derivative, or a pharmaceutically acceptable salt thereof.
The method of any one of the preceding claims, wherein the larazotide or larazotide derivative is locally administered to the tissue.
A pharmaceutical composition comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO:
- 1) for inhibiting ROCK activity in a tissue, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.
Dependencies are inferred from the claim text.